ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. The efficacy and safety of adeno-associa…

The efficacy and safety of adeno-associated virus-mediated gene therapy for CNGA3- and CNGB3-associated achromatopsia: A genotype-aware systematic review and meta-analysis

Survey of Ophthalmology·August 2
OphthalmologyLimited evidenceAchromatopsiaCNGA3-Associated AchromatopsiaCNGB3-Associated AchromatopsiaSystematic Review And Meta-AnalysisAdeno-Associated Virus VectorGene TherapyMixed

Summary

View source

What was studied

Efficacy and safety of AAV-mediated gene therapy for CNGA3- and CNGB3-associated achromatopsia, pooling 9 human studies identified via systematic search from inception to March 2026.

Key findings

Gene therapy produced a statistically significant but modest improvement in BCVA (mean difference: +2.65 ETDRS letters) and contrast sensitivity; color discrimination showed small but significant gains; retinal sensitivity did not improve significantly. Adverse events occurred in ~29% of cases but were generally mild and transient. Dose-stratified analysis suggested a non-linear response favoring lower-to-intermediate doses. Evidence of benefit was primarily in CNGA3-associated disease; efficacy in CNGB3-associated achromatopsia remains uncertain.

Study limitations

- Evidence base is small (9 studies), limiting statistical power and generalizability. - Genotype-specific conclusions are asymmetric — CNGB3 outcomes are insufficiently characterized. - Follow-up reflects short- to mid-term data only; long-term durability is unknown.

Clinical implications

AAV gene therapy for achromatopsia appears safe short-term and may offer modest visual benefit, particularly for CNGA3 patients — but the gains are small and CNGB3 evidence is weak. Clinicians should counsel patients on realistic expectations and the need for longer-term follow-up data before broader adoption.

Caveats

  • Sample size tag reflects number of included studies (n=9), not total patient count — individual patient N was not reported in the abstract.
  • The DOI year (2026) is consistent with today's date but is unusually recent; the abstract contains a minor typo ('evaluat') which does not affect interpretation.
  • The non-linear dose-response finding (lower/intermediate doses outperforming highest dose) is derived from stratified subgroup analysis and should be interpreted with caution given the small evidence base.

Related Questions

Explore related topics

What are the current clinical outcomes of AAV gene therapy for inherited retinal dystrophies?How does CNGA3 versus CNGB3 genotype affect visual prognosis in achromatopsia?What dose-response relationships have been observed in ocular gene therapy trials?

Publication Details

Year
2026
Journal
Survey of Ophthalmology
Sample Size
n=9
Source
View article
Keep scrolling
More content below.
Up Next